03/09/2026
For years, we have been fundraising for this exact moment. And praying for it, too.
Today, Atamyo Therapeutics presents promising early results from the first patients treated with ATA-200 gene therapy for LGMD-R5 (LGMD-2C).
The early data is incredibly encouraging:
• Over 90% of muscle fibers expressing the missing SGCG protein
• Significant reductions in markers of muscle damage
• Encouraging improvements in functional testing
For a disease that causes progressive muscle weakness in childhood, results like this are something families have been hoping and praying for from the moment they hear their child’s diagnosis. We are beyond thrilled by these promising results and it truly feels like a miracle. There was a time where we never thought these incredible results were even possible.
This clinical trial, led by Dr. Barry Byrne at the University of Florida, is part of the research The Dion Foundation is helping advance, and it would not be possible without the incredible support of our community who continues to stand beside us in this fight.
To everyone who has supported our mission, donated, run races, attended events, shared our posts and believed in this fight, this progress belongs to you, too 🩵
Behind every breakthrough are families who refused to give up. For Peter. For Maggie. For every child still waiting.
Our mission. Your help.
